FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1965053406> ?p ?o ?g. }

• W1965053406 abstract "In first-line treatment of metastatic breast cancer, the best use of the available therapeutic agents is unclear. This study evaluated the efficacy and safety of combined therapy with bevacizumab and gemcitabine.Women who were to undergo first-line treatment for locoregionally recurrent or metastatic breast cancer were eligible. Patients must have received a taxane-containing regimen in the neoadjuvant and/or adjuvant setting with a ≥ 12-month disease-free interval.This was a single-arm, phase II trial. On day 1 of each 14-day cycle, patients received gemcitabine (2500 mg/m(2)) followed by bevacizumab (10 mg/kg). Patients were treated until complete response, progressive disease (PD), or intolerable toxicity. The primary endpoint was progression-free survival (PFS).Fifty-two women were enrolled and treated. The median PFS was 4.8 months (95% confidence interval [CI], 3.4-7.6), the 1-year overall survival rate was 68.7% (95% CI, 54.1%-79.5%), and the response rate was 21.4% (95% CI, 10.3%-36.8%). The clinical benefit rate was 35.7%. The median PFS in the triple-negative (n = 19) and non-triple-negative (n = 33) subsets was 3.9 months (95% CI, 2.7-11.7) and 4.9 months (95% CI, 3.4-8.1), respectively. The most common (all grades) drug-related adverse events (AEs) were nausea (51.9%), fatigue (46.2%), decreased appetite (25.0%), and anemia (25.0%). The most common grade 3 or grade 4 drug-related AEs were neutropenia (13.5%), leukopenia (11.5%), and hypertension (7.7%).Although the gemcitabine-bevacizumab doublet appears active, the median PFS was lower than expected. There were no unexpected safety signals at this dose and schedule of this combination." @default.
• W1965053406 created "2016-06-24" @default.
• W1965053406 creator A5000035636 @default.
• W1965053406 creator A5001002111 @default.
• W1965053406 creator A5004557221 @default.
• W1965053406 creator A5008024543 @default.
• W1965053406 creator A5016064449 @default.
• W1965053406 creator A5017727029 @default.
• W1965053406 creator A5022422153 @default.
• W1965053406 creator A5027795459 @default.
• W1965053406 creator A5028033679 @default.
• W1965053406 creator A5029337682 @default.
• W1965053406 creator A5035861905 @default.
• W1965053406 creator A5047450557 @default.
• W1965053406 creator A5050943019 @default.
• W1965053406 creator A5063636021 @default.
• W1965053406 creator A5065056301 @default.
• W1965053406 creator A5074528165 @default.
• W1965053406 creator A5077274168 @default.
• W1965053406 creator A5080353405 @default.
• W1965053406 creator A5086512140 @default.
• W1965053406 date "2012-10-01" @default.
• W1965053406 modified "2023-10-05" @default.
• W1965053406 title "Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer" @default.
• W1965053406 cites W142069643 @default.
• W1965053406 cites W1539571840 @default.
• W1965053406 cites W1799968499 @default.
• W1965053406 cites W1914910183 @default.
• W1965053406 cites W1997838307 @default.
• W1965053406 cites W2008051049 @default.
• W1965053406 cites W2013246214 @default.
• W1965053406 cites W2022075549 @default.
• W1965053406 cites W2027260716 @default.
• W1965053406 cites W2033329878 @default.
• W1965053406 cites W2053864737 @default.
• W1965053406 cites W2071730404 @default.
• W1965053406 cites W2075213874 @default.
• W1965053406 cites W2096451984 @default.
• W1965053406 cites W2098333537 @default.
• W1965053406 cites W2102118972 @default.
• W1965053406 cites W2103563357 @default.
• W1965053406 cites W2115432999 @default.
• W1965053406 cites W2116280772 @default.
• W1965053406 cites W2121415861 @default.
• W1965053406 cites W2126275851 @default.
• W1965053406 cites W2128095147 @default.
• W1965053406 cites W2131770017 @default.
• W1965053406 cites W2135791859 @default.
• W1965053406 cites W2135800076 @default.
• W1965053406 cites W2139248078 @default.
• W1965053406 cites W2143844247 @default.
• W1965053406 cites W2151631271 @default.
• W1965053406 cites W2153982924 @default.
• W1965053406 cites W2159329940 @default.
• W1965053406 cites W2167224460 @default.
• W1965053406 doi "https://doi.org/10.1016/j.clbc.2012.07.004" @default.
• W1965053406 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23040000" @default.
• W1965053406 hasPublicationYear "2012" @default.
• W1965053406 type Work @default.
• W1965053406 sameAs 1965053406 @default.
• W1965053406 citedByCount "7" @default.
• W1965053406 countsByYear W19650534062014 @default.
• W1965053406 countsByYear W19650534062015 @default.
• W1965053406 countsByYear W19650534062019 @default.
• W1965053406 crossrefType "journal-article" @default.
• W1965053406 hasAuthorship W1965053406A5000035636 @default.
• W1965053406 hasAuthorship W1965053406A5001002111 @default.
• W1965053406 hasAuthorship W1965053406A5004557221 @default.
• W1965053406 hasAuthorship W1965053406A5008024543 @default.
• W1965053406 hasAuthorship W1965053406A5016064449 @default.
• W1965053406 hasAuthorship W1965053406A5017727029 @default.
• W1965053406 hasAuthorship W1965053406A5022422153 @default.
• W1965053406 hasAuthorship W1965053406A5027795459 @default.
• W1965053406 hasAuthorship W1965053406A5028033679 @default.
• W1965053406 hasAuthorship W1965053406A5029337682 @default.
• W1965053406 hasAuthorship W1965053406A5035861905 @default.
• W1965053406 hasAuthorship W1965053406A5047450557 @default.
• W1965053406 hasAuthorship W1965053406A5050943019 @default.
• W1965053406 hasAuthorship W1965053406A5063636021 @default.
• W1965053406 hasAuthorship W1965053406A5065056301 @default.
• W1965053406 hasAuthorship W1965053406A5074528165 @default.
• W1965053406 hasAuthorship W1965053406A5077274168 @default.
• W1965053406 hasAuthorship W1965053406A5080353405 @default.
• W1965053406 hasAuthorship W1965053406A5086512140 @default.
• W1965053406 hasConcept C121608353 @default.
• W1965053406 hasConcept C126322002 @default.
• W1965053406 hasConcept C141071460 @default.
• W1965053406 hasConcept C143998085 @default.
• W1965053406 hasConcept C197934379 @default.
• W1965053406 hasConcept C203092338 @default.
• W1965053406 hasConcept C2775930923 @default.
• W1965053406 hasConcept C2776694085 @default.
• W1965053406 hasConcept C2777063308 @default.
• W1965053406 hasConcept C2777511904 @default.
• W1965053406 hasConcept C2777802072 @default.
• W1965053406 hasConcept C2780258809 @default.
• W1965053406 hasConcept C2780873365 @default.
• W1965053406 hasConcept C2781413609 @default.
• W1965053406 hasConcept C31760486 @default.
• W1965053406 hasConcept C530470458 @default.

• next